Anavex Life Sciences Reports $13.2 Million Net Loss in Q3 Fiscal 2025

Anavex Life Sciences Corp. has reported its financial results for the third quarter of fiscal 2025, revealing a net loss of $13.2 million, or $0.16 per share, compared to a net loss of $12.2 million, or $0.14 per share, for the same period in the previous year. For the nine months ended June 30, 2025, the company recorded a net loss of $36.6 million, or $0.43 per share, up from a loss of $31.4 million, or $0.38 per share, in the prior year. The increase in net loss is attributed to higher operating expenses and a decrease in other income, primarily due to reduced research and development incentive income and lower interest income.

Total operating expenses for the three months ended June 30, 2025, were $14.5 million, slightly down from $14.6 million in the same quarter of 2024. Research and development expenses decreased to $10.0 million from $11.8 million year-over-year, primarily due to the completion of a large manufacturing campaign for ANAVEX®2-73 and a reduction in costs associated with the Alzheimer’s program. However, general and administrative expenses rose to $4.5 million from $2.8 million, driven by increased legal fees and stock-based compensation.

Anavex continues to focus on its clinical development pipeline, which includes ANAVEX®2-73, currently in trials for Alzheimer’s disease, Parkinson’s disease, and Rett syndrome. The company has not generated any revenue since its inception in 2004 and relies on external financing to support its operations. As of June 30, 2025, Anavex had cash and cash equivalents of $101.2 million, down from $132.2 million at the end of the previous fiscal year. The decrease is attributed to cash used in operations, which totaled $30.4 million for the nine-month period.

In terms of strategic developments, Anavex entered into a Sales Agreement with TD Securities on July 25, 2025, allowing the company to offer and sell up to $150 million in shares of common stock. This agreement is part of Anavex's ongoing efforts to secure funding for its clinical trials and operational needs. The company also has an unused amount of $110.8 million under its existing 2023 Purchase Agreement with Lincoln Park Capital Fund, which allows for additional capital raising.

Looking ahead, Anavex remains focused on advancing its clinical trials and preparing for future development of its pipeline compounds. The company anticipates continued negative cash flows from operations and is actively seeking to establish partnerships to facilitate the commercialization of its product candidates. The management believes that its current working capital will be sufficient to meet operational needs for the next 12 months, although the timing and outcomes of clinical trials remain uncertain.